Pierre Fabre Partners with XtalPi to Advance AI-Driven Drug Discovery

Last edition

Home › News › Drug Discovery & Development

Pierre Fabre Partners with XtalPi to Advance AI-Driven Drug Discovery

Laboratoires Pierre Fabre and XtalPi Holdings have entered into a collaboration agreement to discover novel clinical candidates across multiple research programmes, primarily targeting oncology, with potential applications in dermatology and rare diseases.

Under the agreement, XtalPi will deploy its integrated artificial intelligence (AI) capabilities and robotics platform to design and deliver novel small-molecule therapeutics against undisclosed targets. Laboratoires Pierre Fabre will contribute its expertise in disease biology, drug discovery, translational research and clinical development to evaluate and advance the most promising compounds. The pharmaceutical company will also oversee subsequent clinical and commercial development.

The collaboration will focus on challenging and historically difficult-to-drug targets, an area associated with significant unmet medical needs and opportunities for innovative drug discovery.

For Laboratoires Pierre Fabre, the agreement represents a strategic addition to its research and development (R&D) roadmap, aimed at strengthening its drug discovery capabilities. For XtalPi, the partnership expands its efforts to apply AI and robotics to de novo drug discovery.

Raymond Zheng, Head of Integrated Drug Discovery at XtalPi, said, "We are honoured to enter into this collaboration with Laboratoires Pierre Fabre, a respected international pharmaceutical company. This partnership combines XtalPi's AI and robotics capabilities with Laboratoires Pierre Fabre's established therapeutic development expertise. We aim to advance promising preclinical candidates to benefit patients with unmet medical needs."

Francesco Hofmann, Head of Pharma Research and Development at Laboratoires Pierre Fabre, said, "Partnering with XtalPi represents an important milestone for us. Leveraging the expertise of XtalPi on AI to accelerate the delivery of high-quality clinical candidates for multiple targets is a critical addition to our R&D Data and AI roadmap and to our discovery engine".

The agreement includes an upfront payment, multiple milestone payments and downstream economic participation. The companies have not disclosed the specific financial terms.

Read more on:
artificial intelligence Francesco Hofmann Laboratoires Pierre Fabre Rare diseases Raymond Zheng XtalPi Holdings

More news about: drug discovery & development | Published by Abha Rustagi | November - 09 - 2026

Last news about this category